Windward Bio Announces Closing of $251.2 Million Initial Public Offering and Concurrent Private Placement, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Key Highlights
- ➤$251.2 million gross proceeds from IPO and concurrent private placement
- ➤IPO sold 11,838,234 shares at $17.00, including fully exercised overallotment
- ➤Sanofi bought $50.0 million of shares and pre-funded warrants privately
- ➤WWB began Nasdaq Global Select Market trading on November 13, 2026
- ➤WIN378 is being evaluated in Phase 2/3 asthma and Phase 2 COPD studies
BASEL, Switzerland, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced the closing of its initial public offering of 11,838,234 common shares, which includes the full exercise of the underwriters' option to purchase an additional 1,544,117 common shares, at a public offering price of $17.00 per share. Windward's common shares began trading on the Nasdaq Global Select Market under the ticker symbol "WWB" on November 13, 2026. The gross proceeds to Windward from the initial public offering and the concurrent private placement (see below) were approximately $251.2 million. All of the common shares were offered by Windward.
In addition to the common shares sold in the initial public offering, Windward announced the closing of the concurrent sale of 1,532,691 common shares and pre-funded warrants to purchase 1,408,485 common shares, in each case at the initial public offering price per common share, in a private placement to Sanofi Foreign Participations B.V. for an aggregate purchase price of $50.0 million. The sale of the common shares and the pre-funded warrants was not registered under the Securities Act of 1933, as amended (the “Securities Act”).
Get started
Create a free account to read the full story.
